




Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)


WHAT ARE TMAs?

Thrombotic microangiopathies (TMAs) are a **group of severe and potentially life-threatening rare disorders that cause blood clots and damage** to the walls of the smallest blood vessels (capillaries and small arteries) in the circulatory system. The blood clots can cause **injury to organs** that may lead to organ failure and death.¹


In some cases, overactivation or dysregulation of the **complement system** can drive or worsen development of TMA. This overactivation **fuels an attack on organs and cells in the body**, including endothelial cells that line blood vessels.¹



THE COMPLEMENT SYSTEM



The complement system is a part of the immune system and is **essential to the body's defense against infection**.²




When the system is **thrown out of balance**, or dysregulated, these proteins can **trigger a dangerous, uncontrolled cascade of reactions** that attack cells and tissues resulting in **harmful inflammation** and the **destruction of healthy cells**.²

Signs, symptoms and complications of TMA include:³⁻⁶



Low platelet count



Red blood cell abnormalities
[i.e., anemia, fragmented red cells (schistocytes)]



Thrombosis (blood clots)



Organ damage, including kidneys, brain and heart



Confusion



Shortness of breath



High blood pressure




Fatigue

WHAT IS HSCT-TMA?

HSCT-TMA is a **rare, severe and potentially life-threatening** type of TMA that **occurs following HSCT**, a procedure to treat some types of cancers and other diseases.^{7,8}

It is thought that factors associated with HSCT (including conditioning regimens, immunosuppressant therapies, infection and other complications) induce **overactivation and/or dysregulation of the complement system**, driving HSCT-TMA.⁸

HOW IS HSCT-TMA DIAGNOSED?



HSCT-TMA symptoms can overlap with those of other conditions, which can lead to a misdiagnosis and/or a significant delay in receiving an accurate diagnosis.⁸

While there are no specific diagnostic tests for HSCT-TMA, consensus criteria recommend monitoring with **routine laboratory tests and evaluation of blood cells** under a microscope to **help make a diagnosis**.^{8,9}

The prognosis can be poor if a TMA is not recognized early. There remains a critical **need for continued innovation to advance scientific understanding of the disease** and **enhance screening and detection** to improve outcomes for people living with HSCT-TMA.⁸



Content created by Alexion, AstraZeneca Rare Disease

References

1. Brocklebank V, et al. Thrombotic microangiopathy and the kidney. *Clin J Am Soc Nephrol*. 2018;13:300-317.
2. Cedzyński M, et al. Editorial: the role of complement in health and disease. *Front Immunol*. 2019;10:1869.
3. Raina R, et al. Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment. *Ther Apher Dial*. 2019;23(1):4-21.
4. Sallée M, et al. Myocardial infarction is a complication of factor H-associated atypical HUS. *Nephrol Dial Transplant*. 2010;25(6):2028-2032
5. Laurence J, et al. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. *Clin Adv Hematol Oncol*. 2016;11(11):2-15.
6. Vorobev A, et al. The phenomenon of thrombotic microangiopathy in cancer patients. *Int. J. Mol. Sci*. 2024;25(16):9055.
7. Ramgopal A, et al. Thrombotic microangiopathy: multi-institutional review of pediatric patients who underwent HSCT. *J. Pers. Med*. 2021;11(6):467.
8. Meri S, et al. The role of complements in HSCT-TMA: basic science to clinical practice. *Adv Ther*. 2022;39(9):3896-3915.
9. Schoettler ML, et al. Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, Associated Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. *Transplant Cell Ther*. 2022;9(3):151-163.

ALEXION and the ALEXION logo are registered trademarks of Alexion Pharmaceuticals, Inc. © 2025, Alexion Pharmaceuticals, Inc. All rights reserved.

US/UNB-HSCT-TMA/0001 V1 06/2025